Rilotumumab

Rilotumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	HGF
Clinical data
ATC code	none;
Identifiers
CAS Number	872514-65-3 ;
ChemSpider	none;
UNII	51WEW898IJ;
KEGG	D09659;
Chemical and physical data
Formula	C6464H9932N1708O2010S46
Molar mass	145207.27 g·mol−1
	(what is this?)

Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.^[1]

Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.^[2]^[3]

References[]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association.
^ "Amgen scraps trials of drug for advanced stomach cancer". yahoo.com. 24 Nov 2014. Retrieved 24 Nov 2014.
^ "Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". 24 November 2014.

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association.

[2] "Amgen scraps trials of drug for advanced stomach cancer". yahoo.com. 24 Nov 2014. Retrieved 24 Nov 2014.

[3] "Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". 24 November 2014.

[1]

[2]

[3]